Medical Device Sustainability: From Green Manufacturing to Business Impact

Why Sustainability is becoming a MedTech Priority

Medical device sustainability is becoming central to conversations around resilience, operational efficiency, supply chain transparency, and long-term competitiveness. As healthcare systems and OEMs seek to reduce healthcare’s 4.4% contribution to global greenhouse gas emissions, greater attention is being paid to how medical products are designed, manufactured, and managed throughout their lifecycles.

However, sustainability in MedTech is more complex than in many other industries. Strict patient safety requirements, infection control protocols, and the widespread use of single-use devices limit conventional circular-economy approaches and create significant waste-management challenges. For example, nearly 90% of operating room waste may be unnecessarily processed as hazardous waste, while sharps waste, including syringes and needles, requires stringent handling and disposal. These realities reinforce the need for sustainability strategies grounded in operational requirements.

As a result, questions about emissions data, supplier transparency, and long-term sustainability readiness are taken seriously as a part of supplier evaluations.

How Regulation differs across Regions

Sustainability regulation is at very different stages across some of the key MedTech markets. In several of them, customer and procurement requirements have already moved ahead of what the law obliges suppliers to do.

Europe: Regulation is the Baseline

Europe remains the primary driver of expectations for green manufacturing in MedTech. Regulatory initiatives such as the EU Clean Industrial Deal (2025), the Industrial Accelerator Act (2026), and the proposed Circular Economy Act are accelerating decarbonization efforts across manufacturing. At the same time, MedTech Europe’s recommendations and EU legal analyses continue to emphasize that patient safety takes precedence whenever environmental objectives conflict with clinical requirements.

Corporate reporting requirements are also evolving. Following the Omnibus I revisions, Corporate Sustainability Reporting Directive (CSRD) obligations now apply to companies with more than 1,000 employees and annual turnover exceeding €450 million, while Wave 2 reporting has been postponed until FY2027. A narrower formal scope does not remove the pressure. It pushes it down the supply chain, as companies still in scope pass data requests to their suppliers.

Following the Omnibus I revisions, CSRD obligations now apply to companies with more than 1,000 employees and annual turnover exceeding €450 million, while Wave 2 reporting has been postponed until FY2027.

United Kingdom: Procurement ahead of Regulation

The strictest sustainability requirement facing medical device suppliers today comes from a customer rather than a regulator. Under NHS England’s net zero supplier roadmap, suppliers bidding for in-scope NHS procurements from 1st April 2027 must publicly report targets and emissions and publish a carbon reduction plan covering all relevant global Scope 1, 2, and 3 emissions.

Carbon reduction plans are not new. They have applied to contracts above £5 million since April 2023 and to all new procurements since April 2024. What changes in 2027 is the boundary, which moves from UK operations and a partial subset of Scope 3 to global operations and all relevant Scope 3 categories.

The implication extends past suppliers holding NHS contracts directly. Around 60% of the NHS carbon footprint sits in its supply chain, so an OEM selling into the NHS must account for its own upstream emissions, including those of its manufacturing partners. A CDMO supplying that OEM falls inside the reporting boundary whether it holds an NHS contract itself.

United States: Transparency without a Framework

Although the United States does not yet have an equivalent MedTech sustainability framework, federal initiatives are placing greater emphasis on supplier transparency, emissions reporting, and resilient supply chains.

Japan

Japan addresses sustainability through industrial strategy rather than dedicated environmental regulation. Its Medical Device Industry Vision sets direction for domestic manufacturing competitiveness, with environmental performance treated as one component of that competitiveness rather than as a separate compliance track.

India

India currently has no MedTech-specific green manufacturing framework. Broader industrial sustainability initiatives, such as the National Medical Devices Policy 2023 continue to strengthen domestic manufacturing and innovation.

Current Landscape and Successful Practices

Medical device sustainability is no longer viewed solely as an additional cost or reporting exercise. Instead, it is becoming part of broader efforts to improve productivity, resilience, and operational efficiency.

Most Emissions can be cut at Net-Zero Cost

Several sustainability initiatives can reduce environmental impact while improving operational performance. McKinsey estimates suggest that initiatives with positive net present value could address about 11% of MedTech emissions, while cost-neutral interventions could reduce another 30%. Overall, around 70% of industry emissions could potentially be reduced at net-zero cost.

Raw Materials and Packaging account for a Significant Share

Material choices represent one of the largest sustainability opportunities. According to McKinsey estimates, approximately 70% of purchased goods emissions originate from metals and plastics, making supplier engagement and material optimization critical.

Packaging also offers substantial opportunities. Lower-carbon materials and packaging redesign can reduce environmental impact while improving transportation efficiency and lowering material use. Studies suggest these measures could reduce packaging-related emissions by as much as 90% by 2040.

Designing for Sustainability

Design decisions carry the most leverage of all. Up to 80% of a product’s environmental impact is determined at the computer-aided design (CAD) and design stage, before any manufacturing decision is made. Material selection, manufacturing complexity, serviceability, and end-of-life options are all effectively set at that point.

Additive Manufacturing as a Circularity Lever

Additive manufacturing can improve material efficiency, reduce waste, and enable design optimization. While maintaining clinical performance and regulatory compliance, it can deliver 22-54% energy savings, reduce embodied greenhouse gas emissions by 38-68%, and enable material recapture rates of up to 80% through in-process powder and runner reuse.

These efforts are increasingly supported by investments in smart automation, AI-enabled inspection, QR-based traceability, and advanced materials integration, enabling manufacturers to improve efficiency while maintaining product quality and regulatory compliance.

The Commercial Case for Sustainability

Despite sustainability initiatives frequently being perceived as cost centers, many organizations have found that well-designed programs can provide measurable commercial value.

Delivering Measurable Returns through Sustainability

One of the most common assumptions about sustainability initiatives is that they increase expenditure. In reality, process optimization and energy-efficient equipment upgrades often achieve positive returns on investment (ROI), while reducing manufacturing costs and emissions.

Building Resilient Supply Chains

Supply chain initiatives can deliver similar benefits. Sustainable localization and dual-sourcing strategies can improve resilience, shorten lead times, and strengthen environmental, social, and governance (ESG) supply chain performance.

SJML’s localization and dual-sourcing initiatives have delivered approximately 10-30% cost optimization, up to 60% lead-time reduction, and a supplier network of more than 400 qualified suppliers across multiple locations, illustrating how sustainability and operational resilience can reinforce one another.

Sustainability as a Procurement Differentiator

Procurement decisions are also evolving. OEMs are increasingly evaluating suppliers based on emissions data, material traceability, and sustainability initiatives, even where formal regulations do not yet apply. Consequently, sustainability investments can strengthen procurement readiness, customer relationships, and long-term competitiveness.

Barriers to Adoption

Despite growing momentum, implementing sustainability initiatives continues to present several challenges.

Financial and Capability Constraints

Investment requirements remain a significant barrier, particularly for smaller suppliers. However, the commercial returns of many sustainability initiatives often outweigh the initial investment.

Workforce Capability

LinkedIn analysis shows that while green job demand has increased by approximately 260%, green skills penetration has grown by only about 60%, creating a significant skills gap across industries.

Regulatory and Industry-Specific Complexities

Regulatory fragmentation continues to create complexity, with sustainability expectations differing across markets. In MedTech, manufacturers must also balance sustainability with patient safety, product performance, infection control, and regulatory compliance. Consequently, practical, category-specific strategies are often more effective than universal circular economy frameworks.

What does this mean for OEMs choosing a Manufacturing Partner

Supplier evaluations are expanding beyond quality, cost, delivery performance, and regulatory compliance. Increasingly, OEMs are assessing whether a medical device contract development and manufacturing organization (CDMO) can:

• Provide activity-based Scope 1-3 emissions data.
• Demonstrate expertise in material optimization and additive manufacturing.
• Maintain resilient, geographically balanced supply chains.
• Support engineering and design close to key markets, particularly Europe.
• Differentiate sustainability claims by device category rather than offering blanket circularity promises.

Future Outlook

Sustainability will not replace quality, cost, and delivery in supplier selection. It is becoming a fourth reading on the same instrument: an indicator of operational maturity and long-term preparedness that procurement teams can evaluate alongside the other three.

In this context, Syrma Johari MedTech combines established regulatory expertise with expanding manufacturing capabilities to support OEMs pursuing more sustainable medical device manufacturing. The company holds ISO 13485:2016 certification, Medical Device Single Audit Program (MDSAP) compliance while continuing to invest in smart automation, AI-enabled inspection, advanced injection molding, 3D printing, and a dedicated precision plastics manufacturing facility.

SJML’s 5-stage ESG roadmap strengthens sustainability from operational initiatives to material-risk preparedness. Key actions include lead-free manufacturing, compliant sourcing, solar-powered EV adoption, supplier risk management, ESG governance, and workforce training. Our approach addresses ISO 14001/50001 and EcoVadis readiness, alognwith PFAS/PTFE risks and supply continuity. Existing achievements include a 60:40 solar energy mix, a fully electrified EV fleet, lead-free solder manufacturing, certified e-waste management, and EN IEC 63000-compliant technical documentation. SJML operates across the United States, Europe, India, and other global markets, supported by a design center in Serbia and a commercial presence in Germany.

Manufacturers that combine quality, regulatory readiness, resilient supply chains, and responsible manufacturing practices will be better positioned to support the next generation of medical device innovation. Syrma Johari MedTech looks forward to exploring what that vision could mean for your next program

References

• Health Care Without Harm & Arup (2019). Health Care’s Climate Footprint. https://global.noharm.org/resources/health-care-climate-footprint-report
• McKinsey & Company (2023). Accelerating the Transition to Net Zero in Life Sciences. https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-the-transition-to-net-zero-in-life-sciences
• Shah et al (2024) Handling ‘carbon footprint’ in orthopedics. https://doi.org/10.1308/rcsann.2023.0052
• World Health Organization. Health-care Waste Factsheet https://www.who.int/news-room/fact-sheets/detail/health-care-waste
• LinkedIn Economic Graph. Global Green Skills Report. https://economicgraph.linkedin.com/research
• European Commission. Corporate Sustainability Reporting. https://finance.ec.europa.eu/capital-markets-union-and-financial-markets/company-reporting-and-auditing/company-reporting/corporate-sustainability-reporting_en
• European Commission. Clean Industrial Deal.https://commission.europa.eu/topics/eu-competitiveness/clean-industrial-deal_en
• European Commission. Circular Economy Action Plan. https://environment.ec.europa.eu/strategy/circular-economy-action-plan_en
• MedTech Europe. Circular Economy Recommendations. https://www.medtecheurope.org/resource-library/